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Background The principal biological processes that characterize heart failure with a preserved ejection fraction (HFpEF) are
systemic inflammation, epicardial adipose tissue accumulation, coronary microcirculatory rarefaction, myocardial
fibrosis and vascular stiffness; the resulting impairment of left ventricular and aortic distensibility (especially when
accompanied by impaired glomerular function and sodium retention) causes increases in cardiac filling pressures
and exertional dyspnoea despite the relative preservation of left ventricular ejection fraction. Independently of their
actions on blood glucose, sodium–glucose co-transporter 2 (SGLT2) inhibitors exert a broad range of biological
effects (including actions to inhibit cardiac inflammation and fibrosis, antagonize sodium retention and improve
glomerular function) that can ameliorate the pathophysiological derangements in HFpEF. Such SGLT2 inhibitors exert
favourable effects in experimental models of HFpEF and have been found in large-scale trials to reduce the risk for
serious heart failure events in patients with type 2 diabetes, many of whom were retrospectively identified as having
HFpEF.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Study design The EMPEROR-Preserved Trial is enrolling ≈5750 patients with HFpEF (ejection fraction >40%), with and without
type 2 diabetes, who are randomized to receive placebo or empagliflozin 10 mg/day, which is added to all appropriate
treatments for HFpEF and co-morbidities.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Study aims The primary endpoint is the time-to-first-event analysis of the combined risk for cardiovascular death or hospitaliza-
tion for heart failure. The trial will also evaluate the effects of empagliflozin on renal function, cardiovascular death,
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all-cause mortality and recurrent hospitalization events, and will assess a wide range of biomarkers that reflect
important pathophysiological mechanisms that may drive the evolution of HFpEF. The EMPEROR-Preserved Trial
is well positioned to determine if empagliflozin can have a meaningful impact on the course of HFpEF, a disorder for
which there are currently few therapeutic options.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Keywords Heart failure • Diabetes • SGLT2 inhibitors • Trial design
Introduction
The two primary phenotypes of chronic heart failure are heart
failure with a reduced ejection fraction (HFrEF) and heart fail-
ure with a preserved ejection fraction (HFpEF).1 The principal
biological processes that characterize HFrEF are cardiomyocyte
loss and stretch; the resulting enlargement of the left ventricle
promotes the activation of neurohormonal systems that cause
sodium retention, systemic vasoconstriction and adverse cham-
ber remodelling, leading to further cardiomyocyte loss and sys-
tolic dysfunction.2,3 In contrast, the principal biological processes
that characterize HFpEF are systemic inflammation, epicardial adi-
pose tissue accumulation, coronary microcirculatory rarefaction,
myocardial fibrosis and vascular stiffness2–6; the resulting impair-
ment of left ventricular and aortic distensibility (especially when
accompanied by impaired glomerular function and sodium reten-
tion) causes increases in cardiac filling pressures and exertional
dyspnoea despite the relative preservation of left ventricular ejec-
tion fraction (LVEF).7 The systemic inflammation in HFpEF can
also cause changes in mitochondrial function and in the mass and
composition of skeletal muscle,8 which can contribute to exercise
intolerance in this disorder.
The treatment of HFrEF is primarily directed towards inter-
ference with deleterious neurohormonal systems (i.e. sympa-
thetic nervous system, renin–angiotensin system, aldosterone and
neprilysin) that are responsible for adverse cardiac remodelling.
Pharmacological blockade of these pathways has been shown to
reduce morbidity and mortality in large-scale randomized con-
trolled trials.9 In contrast, therapeutic interventions that can suc-
cessfully ameliorate the derangement of biological pathways in
HFpEF are still being explored. Mineralocorticoid receptor antago-
nists and neprilysin inhibitors have been shown to have favourable
effects on cardiac structure and function andmay potentially reduce
the risk for serious cardiac events in these patients,10–12 but the
evidence to date is inconclusive.
Sodium–glucose co-transporter 2 (SGLT2) inhibitors were
developed originally as antihyperglycaemic drugs. However, inde-
pendently of their actions on blood glucose, these drugs exert
a broad range of biological effects (including actions to inhibit
cardiac inflammation and fibrosis, as well as to antagonize sodium
retention and improve glomerular function) that position them
to interfere with the principal pathophysiological derangements
in HFpEF.13–17 SGLT2 inhibitors exert favourable effects in exper-
imental models of HFpEF18 and in large-scale trials have been
found to reduce the risk for serious heart failure events in patients
with type 2 diabetes,19–22 who are prone to develop HFpEF.23,24 ..
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Figure 1 Design for the EMPEROR-Preserved Trial.
Therefore, SGLT2 inhibitors may represent an important advance
in the treatment of HFpEF, either alone or in combination with
mineralocorticoid receptor antagonists and neprilysin inhibitors, if
the latter classes of drugs prove to be effective in this disorder in
ongoing trials (Figure 1).
We are evaluating the effects of empagliflozin in two large-scale
clinical trials, one focused on patients with a preserved ejec-
tion fraction (EMPEROR-Preserved, NCT03057951) and the
other focused on patients with a reduced ejection fraction
(EMPEROR-Reduced, NCT03057977). The two trials, taken
together, constitute the EMPEROR Program. This paper describes
the intent and design of the EMPEROR-Preserved Trial.
Trial structure and oversight
The EMPEROR-Preserved Trial is a Phase III international, multicen-
tre, randomized, double-blind, parallel-group, placebo-controlled
trial that is evaluating the effects of empagliflozin on morbidity
and mortality in patients with established HFpEF, with or without
type 2 diabetes. The trial is being carried out in accordance with the
principles of the Declaration of Helsinki and the International Con-
ference on Harmonization Good Clinical Practice guidelines. The
conduct of the study is approved by an institutional review board
for each participating centre, and all participants provide written
informed consent before study entry. The registration identifier
on clinicaltrials.gov is NCT03057951. The sponsors of the trial are
Boehringer Ingelheim (Ingelheim, Germany) and Eli Lilly and Com-
pany (Indianapolis, IN, USA).
© 2019 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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The trial was designed by the study’s Executive Committee, the
members of which include academic investigators, as well as rep-
resentatives of Boehringer Ingelheim. The Executive Committee
was responsible for the development of the study protocol and
had scientific oversight on the development of the case report
forms and statistical plan. In addition, the Executive Committee
is overseeing the pace of recruitment, the appropriateness of the
patients enrolled, and the quality and thoroughness of follow-up.
The decisions and recommendations of the Executive Commit-
tee are reached through collaboration and by consensus. National
leaders from key countries play major regional roles in encourag-
ing recruitment and maintaining the commitment and dedication
of investigators. A further committee, the Endpoint Adjudication
Committee, is evaluating all reported and potential clinical events
while blinded to the treatment assignment; these events will be
judged to have met (or not met) prespecified criteria for a pre-
specified endpoint or safety event. An independent committee, the
Data Monitoring Committee, is responsible for ongoing evaluation
of the data that accrue during the course of the trial and is charged
with making recommendations about the continuation or termina-
tion of the trial. At a planned interim analysis, the Data Monitoring
Committee may recommend that the trial is stopped because it
indicates overwhelming efficacy, which will be guided by prespeci-
fied stopping boundaries. The members of the trial committees are
listed in Appendix 1.
Study patients
Participants in the EMPEROR-Preserved Trial are men and women,
aged≥18 years, who have had chronic heart failure (functional class
II, III or IV) for at least 3 months and in whom LVEF is >40% at its
most recent assessment prior to enrolment and in whom no prior
measurement of ejection fraction of ≤40% is recorded. Patients
are required to have elevated N-terminal pro brain natriuretic
peptide (NT-proBNP) levels (i.e. >300 pg/mL in patients without
atrial fibrillation and >900 pg/mL in patients with atrial fibrillation)
and to show evidence of structural changes in the heart (as
evidenced by increases in left atrial size or left ventricular mass)
on echocardiography or a documented hospitalization for heart
failure within 12months of screening. The dose of oral diuretics
must be stable for 1week prior to randomization.
Patients are excluded if: (i) they have a cardiovascular disorder
or are receiving treatments that increase the unpredictability of or
may change their clinical course, independently of heart failure; (ii)
they have an untreated or undertreated cardiovascular condition
that may influence the course of heart failure or tolerability of the
study medications; (iii) they have a significant co-morbid condition
that may influence the clinical course, independently of heart fail-
ure, or (iv) they have any condition that may jeopardize their safety,
limit their participation in the trial or undermine the interpretation
of trial data. All exclusion criteria are listed in Table 1.
Study visits and follow-up
Following a screening period lasting 4–28 days, patients who fulfil
all eligibility criteria are randomized in a double-blinded manner ..
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.. (in a 1:1 manner) to receive placebo or empagliflozin 10 mg/day,
in addition to their usual therapy for heart failure. The dose of
empagliflozin for this trial was selected based on the observed
reduction in the risk for cardiovascular death produced by a dose
of 10 mg/day in a large-scale trial in patients with type 2 diabetes
(Figure 1).25
Randomization is performed by using a permuted block design
with a computer pseudo-random number generator and an interac-
tive response technology system. Randomization is stratified by: (i)
geographical region (North America, Latin America, Europe, Asia,
other); (ii) status of diabetes at screening; (iii) estimated glomeru-
lar filtration rate (eGFR) [Chronic Kidney Disease Epidemiology
Collaboration (CKD-EPI)] of <60 or ≥60mL/min/1.73m,2 and (iv)
pre-randomization LVEF of <50% or ≥50%. It is expected that
approximately half of the patients will not have diabetes at the
time of enrolment. Following randomization, any and all appro-
priate treatment for heart failure or any other medical condition
or co-morbidity may be initiated, adjusted or altered at the clin-
ical discretion of each patient’s physician or health care provider
according to each patient’s needs, except that open-label use of
SGLT2 inhibitors is prohibited.
Patients will be evaluated periodically at prespecified study vis-
its. These assessments will include a description of the patient’s
New York Heart Association functional class, as well as the report-
ing of adverse events. Quality of life related to heart failure will
be evaluated using the Kansas City Cardiomyopathy Question-
naire at randomization, after 3, 8 and 12months of double-blind
treatment, and at the end of double-blind treatment. Various
biomarkers and end-organ functional assessments will include
(but not be restricted to) the periodic measurement of glycated
haemoglobin, NT-proBNP, renal function (including eGFR and uri-
nary albumin-to-creatinine ratio) and liver function tests; blood
samples will be banked for future biomarker analyses.
Investigators are expected to meticulously document all rel-
evant clinical events that occur from the time of randomization
until trial completion. All randomized patients will be followed for
the occurrence of prespecified primary and secondary outcome
events for the entire duration of the trial, regardless of whether
they are taking their study medications or are fully compliant with
study procedures.
Primary and secondary endpoints
The primary endpoint of the EMPEROR-Preserved Trial is the
time-to-first-event analysis of the combined risk for adjudicated
cardiovascular death and adjudicated hospitalization for heart fail-
ure. The primary analysis will be based on the intention-to-treat
principle and include all randomized patients (from the day of ran-
domization until the end of the planned treatment period), whether
or not they continue to receive the study medications. During the
trial close-out period, patients will return for an end-of-treatment
visit and will be followed for an additional 30 days off treatment.
Primary events occurring during this follow-up period will not be
included in the primary analysis of efficacy, but will be included in
a separate analysis.
Differences between the placebo and empagliflozin groups in the
primary endpoint will be assessed for statistical significance using
© 2019 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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Table 1 Exclusion criteria for the EMPEROR-Preserved Trial
Cardiovascular diseases or treatments that increase the unpredictability of or change the patient’s clinical course, independent of heart failure
Myocardial infarction [increase in cardiac enzymes in combination with symptoms of ischaemia or new ischaemic electrocardiography (ECG)
changes], coronary artery bypass graft surgery, or other major cardiovascular surgery, stroke or transient ischaemic attack in the past 90 days
Heart transplant or listing for heart transplant. Currently implanted left ventricular assist device
Cardiomyopathy based on infiltrative diseases (e.g. amyloidosis), accumulation diseases (e.g. haemochromatosis, Fabry disease), muscular
dystrophies, cardiomyopathy with reversible causes (e.g. stress cardiomyopathy), hypertrophic obstructive cardiomyopathy or known pericardial
constriction
Any severe (obstructive or regurgitant) valvular heart disease, expected to lead to surgery during the trial period
Acute decompensated heart failure requiring intravenous diuretics, vasodilators, inotropic agents or mechanical support within 1 week of
screening and during the screening period prior to randomization
Implant of a cardioverter defibrillator within 3 months prior to screening
Cardiac resynchronization therapy
Untreated or undertreated cardiovascular conditions that might influence the course of heart failure or the tolerability of the study medications
Atrial fibrillation or atrial flutter with a resting heart rate of >110 bpm documented by ECG at screening
Systolic blood pressure of ≥180mmHg at randomization. If the systolic blood pressure is 151–179mmHg, the patient should be receiving at least
three antihypertensive drugs
Symptomatic hypotension and/or systolic blood pressure of <100mmHg at screening or at randomization
Significant co-morbid conditions that might influence the clinical course, independent of heart failure
Chronic pulmonary disease requiring home oxygen, oral corticosteroid therapy or hospitalization for exacerbation within 12months; significant
chronic pulmonary disease or primary pulmonary arterial hypertension
Acute or chronic liver disease, defined by serum levels of transminases or alkaline phosphatase more than three times the upper limit of normal at
screening
Impaired renal function, defined as an estimated glomerular filtration rate of <20mL/min/1.73m2 (Chronic Kidney Disease Epidemiology
Collaboration) or requiring dialysis at the time of screening
Haemoglobin of <9 g/dL at screening
Major surgery (major according to the investigator’s assessment) performed within 90 days prior to screening, or major scheduled elective
surgery (e.g. hip replacement) within 90 days after screening
Gastrointestinal surgery or gastrointestinal disorder that might interfere with trial medication absorption
Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell
carcinoma of the skin, in situ carcinoma of the uterine cervix, or low-risk prostate cancer (patients with pre-treatment prostate-specific antigen
levels of <10 ng/mL, and biopsy Gleason scores of ≤6 and clinical stage T1c or T2a)
Presence of any disease other than heart failure that results in a life expectancy of <1 year (in the opinion of the investigator)
Any condition that might jeopardize patient safety, limit the patient’s participation in the trial, or undermine the interpretation of trial data
Current use or prior use of a sodium–glucose cotransporter 2 (SGLT2) inhibitor or combined inhibitor of SGLT1 and SGLT2 within 12weeks
prior to screening or randomization. Discontinuation of a SGLT2 inhibitor or combined inhibitor of SGLT1 and SGLT2 inhibitor for the purposes
of study enrolment is not permitted
Known allergy or hypersensitivity to any SGLT2 inhibitors
History of ketoacidosis
Need or wish to continue the intake of restricted medications or any drug considered likely to interfere with the safe conduct of the trial
Current enrolment in another investigational device or drug study or completion within <30 days of a trial of another investigational device or
drug study. Receipt of any investigative treatment other than the study medications for this trial
Chronic alcohol or drug abuse or any condition that, in the investigator’s opinion, will make the patient unlikely to fulfil the trial requirements or
complete the trial
Pregnancy, current breast-feeding or intention to become pregnant while in the trial
Any other clinical condition that might jeopardize patient safety during participation in this trial or prevent the subject from adhering to the trial
protocol
a Cox proportional hazards model, with prespecified covariates
of age, gender, geographical region, diabetes status at baseline,
LVEF and eGFR at baseline. Age, ejection fraction and eGFR
will be included in the model as continuous variables. The most
important prespecified subgroup analysis will compare the effects
of empagliflozin on the risk for major cardiovascular events in
patients with and without diabetes at the time of randomization.
Secondary endpoints will be analysed in a stepwise hierarchical
manner in order to preserve the overall type 1 error rate at a ..
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..
. study-wide level of 0.05 (two-sided). The first-listed secondary
endpoint is the occurrence of adjudicated hospitalization for heart
failure (including first and recurrent events), which will be evaluated
using a joint frailty model that includes the consideration of
cardiovascular death as a potential source of informative censoring.
If this endpoint is successfully achieved, the analysis will proceed
to an analysis of the second-listed secondary endpoint [i.e. the
slope of the change in eGFR (CKD-EPI) from baseline], which
will be evaluated by a random coefficient model allowing for
© 2019 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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random intercept and random slope per patient. If the trial is
not stopped at the interim analysis, an 𝛼-value of 0.001 will be
assigned to the eGRF analysis and the remaining 𝛼-value will be
applied to a patient-level meta-analysis, which will be prospectively
carried out to evaluate the effects of empagliflozin (vs. placebo) in
both the EMPEROR-Reduced and EMPEROR-Preserved Trials. The
endpoints for this meta-analysis include a composite renal endpoint
as well as cardiovascular death, time to onset of diabetes in patients
without diabetes, and all-cause mortality; these are also designated
as secondary endpoints in the individual trials. If the null hypothesis
is not rejected at any step in the process of sequential analysis,
subsequent hypothesis testing will be considered to be exploratory
and P-values will be considered to be nominal. All safety analyses
will be based on the treated set, which will consist of all patients
who receive at least one dose of the trial medication.
Sample size calculations and study
conduct
The trial will be carried out as an event-driven study and will con-
tinue until 841 adjudicated primary endpoint events have occurred,
unless the trial is stopped early following a recommendation by the
Data Monitoring Committee. This number of events is expected to
provide the ability to detect a 20% difference in the relative risk for
a primary endpoint event (two-sided), with 90% power. Based on
the assumption of a 10% event rate per year in the placebo arm
and a recruitment period of 18months and a follow-up period of
20months, we projected that the trial would need to enrol at least
4100 patients. However, in anticipation of unavoidable delays, the
original protocol specified the option of increasing the number of
randomized patients to 6000 if the accumulation of primary end-
point events over calendar time was slower than expected. Based
on ongoing monitoring of event accrual, we reset the recruitment
target at ≈5750 patients (i.e. ≈2875 patients per treatment group).
The target number of patients was recalculated without any knowl-
edge of the unblinded results of the trial and prior to the planned
formal interim analysis of efficacy by the Data Monitoring Commit-
tee. Each patient will be followed for a minimum of 6 months after
randomization.
Subsequent to the accrual of at least 500 primary endpoint
events, the Data Monitoring Committee will carry out one pre-
specified interim efficacy analysis and, based on this analysis, may
recommend the early termination of the study if critical P-values
for a benefit of empagliflozin are achieved for both the primary
endpoint and the analysis of cardiovascular death alone. The crit-
ical P-value is determined by a Hwang–Shih–De Cani 𝛼-spending
function with a parameter 𝛾-value of −8, which at approximately
500 events (60% of the total number of expected events) yields a
one-sided 𝛼-value of 0.001.26
Discussion
A wide range of systemic inflammatory states lead to the accumu-
lation and inflammation of epicardial adipose tissue and perivas-
cular fat, which act as transducers for the transmission of the ..
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.. inflammatory process to the myocardium and aorta.4,27,28 The
inflammation of myocardial and vascular tissues causes disruption
of the microvascular blood supply, cardiac and adventitial fibro-
sis and impaired distensibility of the cardiac chambers and great
vessels.2–6,29 The inflammatory process can also trigger the release
of various cell-signalling molecules and enzymes from adipose tis-
sue, including aldosterone, neprilysin and leptin30; the resulting
sodium retention and expansion of plasma volume lead to a dis-
proportionate increase in cardiac filling pressures when the left
ventricle cannot expand as a result of microvascular rarefaction and
fibrosis.31 The systemic inflammatory process can also lead to renal
injury (and other co-morbidities) as a result of cytokine-mediated
inflammation and fibrosis of the renal parenchyma,32,33 and renal
function may deteriorate as a consequence of the glomerular
hyperfiltration seen in type 2 diabetes and obesity,33,34 which are
frequently present in patients with HFpEF.
Treatment with SGLT2 inhibitors is poised to ameliorate many
of the pathophysiological abnormalities seen in HFpEF.14 In clini-
cal trials, the use of SGLT2 inhibitors has been shown to reduce
the quantity of epicardial adipose tissue (independently of effect
on body weight),35–37 and these drugs ameliorate the inflammation
of adipose tissue surrounding the heart and great vessels38,39 and
the associated abnormalities of cardiac filling and aortic distensi-
bility in both experimental and clinical HFpEF.18,40–42 Furthermore,
SGLT2 inhibitors act to inhibit sodium reabsorption in the proxi-
mal renal tubules, in which the majority of renal sodium retention
occurs43–45; this action explains the marked reduction in plasma
and/or interstitial volume and haemoconcentration seen in ran-
domized controlled trials in type 2 diabetes.25,46 Moreover, SGLT2
inhibitors can attenuate renal inflammation and fibrosis.17,47,48
Additionally, the increased delivery of sodium to the macula densa
that results from the inhibition of proximal tubular sodium reab-
sorption leads (through tubuloglomerular feedback) to a reduction
in glomerular hyperfiltration, thereby ameliorating the major mech-
anism of glomerular injury in obesity and type 2 diabetes.33,34,49,50
Given the multiplicity of actions on cardiac, vascular and renal
pathways that are relevant to the pathogenesis of HFpEF, it seems
unlikely that a benefit of empagliflozin in this condition (if found in
this trial) can be ascribed solely to its diuretic effects.46,51
Will these actions of SGLT2 inhibitors on the heart, great ves-
sels and kidneys lead to clinical benefits in patients with HFpEF?
The ongoing EMPEROR-Preserved Trial is designed to specifically
evaluate the effect of empagliflozin on the risk for cardiovascular
death or hospitalization for heart failure in patients with HFpEF, as
well as the drug’s effect on the total number of heart failure hos-
pitalizations. The trial is also examining the ability of empagliflozin
to prevent the time-dependent deterioration of glomerular filtra-
tion, which characterizes patients with HFpEF. Importantly, because
the reported benefits of SGLT2 inhibitors on heart failure do not
appear to be related to their effects on glycaemic control,25,50,51
the trial is enrolling patients with and without diabetes. Based
on current understanding of its enormous range of pleotropic
effects, it is not expected that the pre-treatment glycaemic status of
patients will influence the magnitude or direction of the therapeutic
response to treatment.
© 2019 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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The likelihood that empagliflozin will be shown to have clinical
benefits in the EMPEROR-Preserved Trial is strengthened by the
fact that the drug has already been shown to reduce the risk for
cardiovascular death or heart failure hospitalization and to improve
glomerular function and slow the progression of renal disease
in patients with type 2 diabetes, in most of whom heart failure
was not identified at the time of randomization.25,50 Although
these trials did not fully characterize the phenotype of those who
developed heart failure during the course of follow-up, patients
with type 2 diabetes are particularly prone to the development of
HFpEF.23,24 In post hoc analyses of both the DECLARE-TIMI 58
trial with dapagliflozin and the CANVAS trial with canagliflozin52,53
the use of SGLT2 inhibitors reduced the risk for hospitalization
for heart failure in patients who were reported to have HFpEF at
the time of enrolment or at the time of a heart failure event that
occurred following randomization; however, these data in trials in
patients with type 2 diabetes are sparse and incomplete, and thus
must be considered to be hypothesis-generating. In contrast, the
EMPEROR-Preserved Trial is specifically designed to determine if
empagliflozin can treat patients with established HFpEF, whether or
not they have diabetes. Importantly, the EMPEROR-Preserved Trial
plans to evaluate a diverse array of circulating measures of adiposity
and inflammation, as well as biomarkers of cardiac and renal injury.
It is therefore well positioned to identify the mechanisms by
which empagliflozin is beneficial if it achieves success in its planned
endpoints.
Given its projected sample size of ≈5750 patients, the
EMPEROR-Preserved Trial is likely to be the largest trial ever
carried out in patients with HFpEF. It will provide critical insights
into the pathogenesis of the disease and the mechanisms that
contribute to morbidity and mortality in this disorder. It has
been hypothesized that the activation of certain mediators (e.g.
the leptin–aldosterone–neprilysin axis) plays an important role
in the development of HFpEF in many patients.30 Interestingly,
the biological actions of the SGLT2 inhibitors evaluated in the
EMPEROR-Preserved Trial can be regarded as opposite to those
of leptin,32 whereas other ongoing trials are evaluating the efficacy
of inhibitors of aldosterone and neprilysin.54,55 The totality of
evidence from these trials may establish a neurohormonal basis
for the treatment of HFpEF in a manner that parallels that which
exists for patients with HFrEF.14,56,57
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